Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 30
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Gan To Kagaku Ryoho ; 50(4): 493-495, 2023 Apr.
Artigo em Japonês | MEDLINE | ID: mdl-37066465

RESUMO

Hyperammonemia induced by 5-fluorouracil(5-FU)is known as a rare adverse event, but there are few reports of hyperammonemia occurring during FP(5-FU plus CDDP)treatment for esophageal cancer. We report a case of esophageal cancer with consciousness disorder due to hyperammonemia during FP treatment with an examination of some of the relevant literature. The patient was a man of approximately 70 years of age who was received FP treatment. He showed consciousness disorder on day 4. A blood test showed hyperammonemia(427µg/dL), which was considered to be the cause of his consciousness disorder. He was treated with branched chain amino acid infusion, lactulose and kanamycin and made a full recovery. An operation for esophageal cancer was performed after 3 months and he is currently followed up without recurrence. Hyperammonemia should be considered as a differential diagnosis of consciousness disorder during chemotherapy including 5-FU.


Assuntos
Neoplasias Esofágicas , Hiperamonemia , Masculino , Humanos , Hiperamonemia/induzido quimicamente , Hiperamonemia/tratamento farmacológico , Transtornos da Consciência/induzido quimicamente , Fluoruracila , Neoplasias Esofágicas/tratamento farmacológico , Neoplasias Esofágicas/etiologia , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos
2.
Gan To Kagaku Ryoho ; 50(13): 1697-1699, 2023 Dec.
Artigo em Japonês | MEDLINE | ID: mdl-38303177

RESUMO

In cases of unresectable, locally advanced esophageal cancer, conversion surgery may be considered if chemotherapy produces favorable results and surgical resection is indicated. The use of immune checkpoint inhibitors in chemotherapy for esophageal cancer has expanded, and has increased the number of cases in which conversion surgery becomes possible. The patient in the present report had received a diagnosis of Stage Ⅳa esophageal carcinoma, and a prior nephroureterectomy discouraged the administration of platinum-based agents. Nivolumab and ipilimumab were administered as induction chemotherapy. Despite the achievement of stable disease, the patient's esophageal stricture deteriorated, necessitating surgical intervention. The resected specimen revealed that fewer than 50% of malignant cells remained viable and residual cancer cells were noticeably absent, particularly in the enlarged lymph nodes. We herein present the details of this case and discuss the literature concerning surgery following immune checkpoint inhibitor therapy.


Assuntos
Neoplasias Esofágicas , Linfadenopatia , Humanos , Nivolumabe/uso terapêutico , Ipilimumab/uso terapêutico , Inibidores de Checkpoint Imunológico/uso terapêutico , Neoplasias Esofágicas/tratamento farmacológico , Neoplasias Esofágicas/cirurgia , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
3.
Gan To Kagaku Ryoho ; 46(13): 1990-1992, 2019 Dec.
Artigo em Japonês | MEDLINE | ID: mdl-32157036

RESUMO

A 74-year-old man with anemia visited our department. Esophagogastroduodenoscopy showed a type 2 lesion from the angulus to the antrum. Histopathological findings indicated gastric neuroendocrine carcinoma. Colonoscopy showed a type 1 lesion at the cecum. Distal gastrectomy was performed with D1+lymph node dissection, Roux-en-Y reconstruction, and ileocecal resection with D3 lymph node dissection. The patient was pathologically diagnosed with large-cell neuroendocrine carcinoma in the stomach, pT4a(SE), med, INF a>>b-c, ly1-2, v1(SM, EVG), pN0, pM0, pStageⅡB, and adenocarcinoma (tub1>tub2)of the cecum, pT2(MP), ly1(HE), v1(EVG, SM), pN0, pM0, pStageⅠ. Postoperatively, he received oral S-1 as an adjuvant chemotherapy. His postoperative course was uneventful without any recurrence over 18 months.


Assuntos
Adenocarcinoma , Carcinoma Neuroendócrino , Neoplasias do Ceco/patologia , Neoplasias Primárias Múltiplas , Neoplasias Gástricas , Adenocarcinoma/terapia , Idoso , Protocolos de Quimioterapia Combinada Antineoplásica , Carcinoma Neuroendócrino/terapia , Neoplasias do Ceco/terapia , Ceco , Gastrectomia , Humanos , Masculino , Recidiva Local de Neoplasia , Neoplasias Gástricas/terapia
4.
Appl Microbiol Biotechnol ; 99(6): 2741-50, 2015 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-25549619

RESUMO

In Corynebacterium glutamicum, the phosphoenolpyruvate-dependent sugar phosphotransferase system (PTS) has long been the only known glucose uptake system, but we recently found suppressor mutants emerging from a PTS-negative strain of C. glutamicum ATCC 31833 on glucose agar plates, and identified two alternative potential glucose uptake systems, the myo-inositol transporters encoded by iolT1 and iolT2. The expression of either gene renders the PTS-negative strain WTΔptsH capable of growing on glucose. In the present study, we found a suppressor strain that still grew on glucose even after the iolT1 and iolT2 genes were both disrupted under the PTS-negative background. Whole-genome sequencing of the suppressor strain SPH1 identified a G-to-T exchange at 134 bp upstream of the bglF gene encoding an EII component of the ß-glucoside-PTS, which is found in limited wild-type strains of C. glutamicum. Introduction of the mutation into strain WTΔptsH allowed the PTS-negative strain to grow on glucose. Reverse transcription-quantitative PCR analysis revealed that the mutation upregulates the bglF gene by approximately 11-fold. Overexpression of bglF under the gapA promoter in strain WTΔptsH rendered the strain capable of growing on glucose, and deletion of bglF in strain SPH1 abolished the growth again, proving that bglF is responsible for glucose uptake in the suppressor strain. Simultaneous disruption of three glucokinase genes, glk (Cgl2185, NCgl2105), ppgK (Cgl1910, NCgl1835), and Cgl2647 (NCgl2558), in strain SPH1 resulted in no growth on glucose. Plasmid-mediated expression of any of the three genes in the triple-knockout mutant restored the growth on glucose. These results indicate that C. glutamicum ATCC 31833 has an additional non-PTS glucose uptake route consisting of the bglF-specified EII permease and native glucokinases.


Assuntos
Proteínas de Bactérias/metabolismo , Metabolismo dos Carboidratos , Corynebacterium glutamicum/enzimologia , Glucoquinase/metabolismo , Glucose/metabolismo , Proteínas de Bactérias/genética , Corynebacterium glutamicum/genética , Deleção de Genes , Glucoquinase/genética , Sistema Fosfotransferase de Açúcar do Fosfoenolpiruvato/metabolismo , Plasmídeos/genética , Regiões Promotoras Genéticas
5.
Nihon Shokakibyo Gakkai Zasshi ; 112(12): 2152-9, 2015 Dec.
Artigo em Japonês | MEDLINE | ID: mdl-26638787

RESUMO

We report abdominal bleeding caused by an arteriovenous fistula (AVF) of the gastroepiploic artery. A 20-year-old man visited our hospital with epigastric pain and hypovolemic shock. Contrast-enhanced abdominal computed tomography revealed a high-density region within a huge low-density mass. Angiography revealed AVF of the gastroepiploic artery. Therefore, we performed transcatheter arterial embolization using n-butyl-2-cyanoacrylate (Histoacryl(®)) to control the intraperitoneal hemorrhage.


Assuntos
Fístula Arteriovenosa/complicações , Hemoperitônio/etiologia , Hemorragia/etiologia , Estômago/irrigação sanguínea , Artéria Gastroepiploica/anormalidades , Humanos , Masculino , Adulto Jovem
6.
Hepatogastroenterology ; 61(131): 712-6, 2014 May.
Artigo em Inglês | MEDLINE | ID: mdl-26176062

RESUMO

BACKGROUND/AIMS: It is difficult to estimate the functional reserve of the liver required for safe hepatectomy in patients with severe chronic liver disease The aim of this study was to retrospectively construct simple model based on routine laboratory data to predict both early liver failure (ELF) and mortality from recurrence-free liver failure (MLF) as an index for late liver failure after hepatectomy. METHODOLOGY: Between 2000 and 2004, 196 consecutive patients underwent curative hepatectomy, and data from 127 minor hepatectomies were included in this study. RESULTS: Mean survival time was [mean (SD)] 1252 (670) days after hepatectomy. ELF and MLF were observed in 29 and 13 patients, respectively. PT%, TB, and direct bilirubin (DB) were the best predictors in patients with both ELF and MLF. PT% alone was the best predictor of ELF and MLF with area under ROC curves of 0.70 and 0.81, respectively. By using a preoperative PT% of ≤ 70, we could accurately predict ELF and MLF in 77% and 87% of patients, respectively. ICG-R15 could not accurately predict both ELF and MLF for any cut-off values. CONCLUSIONS: Unlike ICG-R15, PT% is a simple noninvasive index for estimating liver functional reserve to predict both ELF and MLF.


Assuntos
Hepatectomia , Hepatopatias/cirurgia , Falência Hepática/etiologia , Testes de Função Hepática/métodos , Fígado/cirurgia , Idoso , Área Sob a Curva , Bilirrubina/sangue , Biomarcadores/sangue , Doença Crônica , Intervalo Livre de Doença , Feminino , Hepatectomia/efeitos adversos , Hepatectomia/mortalidade , Humanos , Fígado/metabolismo , Fígado/fisiopatologia , Hepatopatias/sangue , Hepatopatias/diagnóstico , Hepatopatias/mortalidade , Hepatopatias/fisiopatologia , Falência Hepática/diagnóstico , Falência Hepática/mortalidade , Falência Hepática/fisiopatologia , Masculino , Pessoa de Meia-Idade , Valor Preditivo dos Testes , Tempo de Protrombina , Curva ROC , Estudos Retrospectivos , Fatores de Tempo , Resultado do Tratamento
7.
Hepatogastroenterology ; 60(125): 955-60, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-23803362

RESUMO

BACKGROUND/AIMS: Advances in chemotherapy have expanded the resectability of colorectal liver (CRC) metastases. We studied treatment results in CRC patients with liver metastases in the era of molecular target-based agents. METHODOLOGY: Based on data collected retrospectively, we analyzed the demographics, operative and pathological outcomes, and adjuvant chemotherapy, of 91 consecutive CRC patients with liver metastases treated between January, 2008 and June, 2010. RESULTS: Of the 91 patients, 42 (46.2%) underwent liver resection (group 1), 41 underwent only resection of the primary tumor without hepatectomy (group 2), and 8 underwent palliative surgery (group 3). According to multivariate analysis, resection of liver metastases was significantly influenced by the number of metastases and the existence of extrahepatic metastases. Disease-free survival (DFS) differed significantly between patients who received adjuvant therapy and those treated by surgery alone (p<0.001). The regimen (p=0.01) and duration (p<0.0001) of adjuvant chemotherapy also affected DFS. Overall survival after 1 and 3 years was 97.6% and 94.0%, respectively, in group 1, 71.9% and 30.6% in group 2, and 33.3% and 0% in group 3. CONCLUSIONS: Although the observation period was short, our findings suggest that high resectability and effective chemotherapy will prolong the survival of patients with colorectal liver metastases.


Assuntos
Neoplasias Colorretais/patologia , Hepatectomia , Neoplasias Hepáticas/secundário , Neoplasias Hepáticas/terapia , Adulto , Idoso , Idoso de 80 Anos ou mais , Quimioterapia Adjuvante , Feminino , Humanos , Neoplasias Hepáticas/mortalidade , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Taxa de Sobrevida
8.
Hepatology ; 54(4): 1273-81, 2011 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-22006857

RESUMO

The prediction of cancer recurrence holds the key to improvement of the postoperative prognosis of patients. In this study, the recurrence of early-stage hepatocellular carcinoma (HCC) after curative hepatectomy was analyzed by the genome-wide gene-expression profiling on cancer tissue and the noncancerous liver tissue. Using the training set of 78 cases, the cytochrome P450 1A2 (CYP1A2) gene in noncancerous liver tissue was identified as the predictive candidate for postoperative recurrence (hazard ratio [HR], 0.447; 95% confidence interval [CI], 0.249-0.808; P = 0.010). Multivariate analysis revealed the statistically significant advantage of CYP1A2 down-regulation to predict recurrence (odds ratio, 0.534; 95% CI, 0.276-0.916; P = 0.036), and the expression of CYP1A2 protein was confirmed immunohistochemically. An independently multi-institutional cohort of 211 patients, using tissue microarrays, validated that loss of expression of CYP1A2 in noncancerous liver tissue as the only predictive factor of recurrence after curative hepatectomy for early-stage HCC (HR, 0.480; 95% CI, 0.256-0.902; P = 0.038). Gene set-enrichment analysis revealed close association of CYP1A2 down-regulation with oxidative stress pathways in liver tissue (P < 0.001, false discovery rate [FDR] = 0.042; P = 0.006, FDR = 0.035). Our results indicate these pathways as the molecular targets to prevent recurrence, as well as the potential prediction of the super high-risk population of HCC using liver tissue.


Assuntos
Carcinoma Hepatocelular/genética , Citocromo P-450 CYP1A2/genética , Regulação Neoplásica da Expressão Gênica , Neoplasias Hepáticas/genética , Recidiva Local de Neoplasia/genética , Estresse Oxidativo/genética , Carcinoma Hepatocelular/patologia , Carcinoma Hepatocelular/cirurgia , Estudos de Casos e Controles , Intervalos de Confiança , Feminino , Perfilação da Expressão Gênica , Estudos de Associação Genética , Hepatectomia/métodos , Humanos , Imuno-Histoquímica , Neoplasias Hepáticas/patologia , Neoplasias Hepáticas/cirurgia , Masculino , Análise em Microsséries , Análise Multivariada , Recidiva Local de Neoplasia/patologia , Razão de Chances , Valor Preditivo dos Testes , Estudos Prospectivos , Valores de Referência , Reprodutibilidade dos Testes , Inclusão do Tecido
9.
Jpn J Clin Oncol ; 42(12): 1197-201, 2012 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-23071288

RESUMO

Choriocarcinoma is an early metastasizing and highly invasive tumor and characterized as a high-level human chorionic gonadotropin-secreting tumor. It normally arises in the gestational trophoblast, gonads and much less frequently in the stomach. Primary gastric choriocarcinoma appears to have a poor prognosis; especially with liver metastasis, the survival period is expected to be <1 month. This unfavorable clinical outcome is partly due to the lack of defined chemotherapy against primary gastric choriocarcinoma. We herein report a case of a 68-year-old male primary gastric choriocarcinoma patient with advanced liver metastases in which germ cell tumor-based chemotherapy achieved a pathological complete response and 2-year disease-free survival.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Coriocarcinoma não Gestacional/tratamento farmacológico , Coriocarcinoma não Gestacional/secundário , Neoplasias Hepáticas/tratamento farmacológico , Neoplasias Hepáticas/secundário , Neoplasias Gástricas/tratamento farmacológico , Idoso , Biomarcadores Tumorais/metabolismo , Coriocarcinoma não Gestacional/patologia , Gonadotropina Coriônica Humana Subunidade beta/metabolismo , Cisplatino/administração & dosagem , Intervalo Livre de Doença , Docetaxel , Etoposídeo/administração & dosagem , Fluoruracila/administração & dosagem , Humanos , Neoplasias Hepáticas/patologia , Neoplasias Hepáticas/cirurgia , Masculino , Neoplasia Residual/cirurgia , Neoplasias Gástricas/patologia , Análise de Sobrevida , Taxoides/administração & dosagem
10.
Ann Surg ; 253(1): 94-100, 2011 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-21233610

RESUMO

OBJECTIVE: To evaluate the gene expression signature of hepatocellular carcinoma (HCC) in relation to the gross morphology. BACKGROUND: Eggel's nodular type of HCC is morphologically subclassified into the single nodular (SN) type, the single nodular type with extranodular growth (SNEG), and the confluent multinodular (CM) type, but their biomolecular differences remain unclear. METHODS: The clinicopathological characteristics and genome-wide gene expressions were analyzed in 275 patients with nodular-type HCC (124 SN-type, 91 SNEG-type, and 60 CM-type) who received curative hepatectomy. RESULTS: Significantly poor prognosis was recognized in CM types in overall survival (P = 0.0020) and recurrence-free survival (P = 0.0066). Analysis of the genome-wide expression patterns revealed significant difference of CM-type HCC from either SN- or SNEG-type HCC. In particular, a stem cell marker EpCAM was dominantly expressed in CM-type HCC. Immunohistochemical studies confirmed the specific expression of EpCAM in HCC cancer cells of CM type. In multivariate analysis, the gross morphology of CM type was significantly associated with EpCAM expression (P = 0.0092), α-fetoprotein (P = 0.0424), "lens culinaris agglutinin-reactive fraction of α-fetoprotein" level (P = 0.0288), and the portal vein invasion (P = 0.0150). Furthermore, EpCAM was predictive for poor prognosis in overall and recurrence-free survivals of patients with CM-type HCC (P = 0.0082 and P = 0.0043, respectively). CONCLUSION: Our studies suggest that the distinct signature of gene expression is closely related to morphological progression in HCC. Especially, EpCAM might play a critical role in the aggressiveness of CM-type HCC.


Assuntos
Carcinoma Hepatocelular/genética , Carcinoma Hepatocelular/patologia , Perfilação da Expressão Gênica , Neoplasias Hepáticas/genética , Neoplasias Hepáticas/patologia , Idoso , Carcinoma Hepatocelular/mortalidade , Estudos de Coortes , Feminino , Hepatectomia , Humanos , Neoplasias Hepáticas/mortalidade , Masculino , Pessoa de Meia-Idade , Análise de Sequência com Séries de Oligonucleotídeos , Valor Preditivo dos Testes , Estudos Retrospectivos , Fatores de Risco , Taxa de Sobrevida
11.
Ann Surg Oncol ; 18(7): 2093-103, 2011 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-21286940

RESUMO

BACKGROUND: Perturbations in the nuclear microenvironment, including transport systems, play a critical role in malignant progression, but the nuclear import abnormalities remain unclear in hepatocarcinogenesis. We analyzed the role of importin in hepatocellular carcinoma (HCC). METHODS: Gene expression profiling of the importin family was performed in HCC tissues. The significance of importin protein expression was analyzed in vitro as well as clinicopathologically. RESULTS: According to the microarray profiles, the importin-α1 was dominantly overexpressed in HCC tissues as compared to the adjacent noncancerous tissues. By means of human HCC cell lines, a knockdown of importin-α1 by its siRNA greatly reduced cellular proliferation by 15.2-26.6% (P < 0.005). Immunohistochemical analysis on tissue samples demonstrated cancer-specific overexpression in 36.3% of HCCs. The overexpression of importin-α1 was correlated statistically with high levels of alfa-fetoprotein ( P = 0.0017), the tumor number (P = 0.0116), histological dedifferentiation (P = 0.0054), tumor morphology (P = 0.0433), portal vein invasion (P = 0.0007), hepatic vein invasion (P = 0.0081), Fc (P = 0.0367), Fc-inf (P = 0.0122), and the tumor, node, metastasis stage (P = 0.0026); this resulted in a significantly poorer prognosis in both overall survival (P = 0.0164) and recurrence-free survival (P = 0.0101). Multivariate analysis of recurrence-free survival revealed importin-α1 expression to be a statistically significant factor (P = 0.0361). In addition, early recurrence after curative resection was observed more frequently in the importin-α1-positive group as compared to the negative group (P = 0.0023). The multivariate analysis identified importin-α1 as the only independent predictor of early recurrence after HCC resection (odds ratio = 5.291, P = 0.0191). CONCLUSIONS: Because importin-α1 might be closely associated with HCC progression, further analysis should be pursued to evaluate it as a novel prognostic target.


Assuntos
Carcinoma Hepatocelular/metabolismo , Neoplasias Hepáticas/tratamento farmacológico , alfa Carioferinas/metabolismo , Idoso , Biomarcadores Tumorais/genética , Biomarcadores Tumorais/metabolismo , Western Blotting , Carcinoma Hepatocelular/genética , Carcinoma Hepatocelular/patologia , Células Cultivadas , Feminino , Perfilação da Expressão Gênica , Veias Hepáticas/metabolismo , Veias Hepáticas/patologia , Humanos , Técnicas Imunoenzimáticas , Fígado/metabolismo , Fígado/patologia , Neoplasias Hepáticas/secundário , Metástase Linfática , Masculino , Invasividade Neoplásica , Recidiva Local de Neoplasia/tratamento farmacológico , Recidiva Local de Neoplasia/patologia , Análise de Sequência com Séries de Oligonucleotídeos , Veia Porta/metabolismo , Veia Porta/patologia , Prognóstico , RNA Interferente Pequeno/genética , alfa Carioferinas/antagonistas & inibidores , alfa Carioferinas/genética
12.
J Hepatol ; 52(1): 63-71, 2010 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-19913935

RESUMO

BACKGROUND & AIMS: We previously identified that high Aurora B expression was associated with hepatocellular carcinoma (HCC) recurrence due to tumor dissemination. In this preclinical study, a novel inhibitor of Aurora B kinase was evaluated as a treatment for human HCC. METHODS: AZD1152 is a selective inhibitor of Aurora B kinase. Twelve human HCC cell lines were analyzed for Aurora B kinase expression and the in vitro effects of AZD1152. The in vivo effects of AZD1152 were analyzed in a subcutaneous xenograft model and a novel orthotopic liver xenograft model. RESULTS: Aurora B kinase expression varied among the human HCC cell lines and was found to correlate with inhibition of cell proliferation, accumulation of 4N DNA, and the proportion of polyploid cells following administration of AZD1152-hydroxyquinazoline-pyrazol-anilide (AZD1152-HQPA). AZD1152-HQPA suppressed histone H3 phosphorylation and induced cell death in a dose-dependent manner. Growth of subcutaneous human HCC xenografts was inhibited by AZD1152 administration. In an orthotopic hepatoma model, treatment with AZD1152 significantly decelerated tumor growth and increased survival. Pharmacobiological analysis revealed that AZD1152 induced the rapid suppression of phosphohistone H3, followed by cellular apoptosis in the liver tumors but not in the normal tissues of the orthotopic models. CONCLUSIONS: Our preclinical studies indicate that AZD1152 is a promising novel therapeutic approach for the treatment of HCC.


Assuntos
Carcinoma Hepatocelular/tratamento farmacológico , Neoplasias Hepáticas/tratamento farmacológico , Organofosfatos/uso terapêutico , Proteínas Serina-Treonina Quinases/antagonistas & inibidores , Quinazolinas/uso terapêutico , Ensaios Antitumorais Modelo de Xenoenxerto , Animais , Aurora Quinase B , Aurora Quinases , Carcinoma Hepatocelular/metabolismo , Carcinoma Hepatocelular/patologia , Morte Celular/efeitos dos fármacos , Linhagem Celular Tumoral , Proliferação de Células/efeitos dos fármacos , Modelos Animais de Doenças , Feminino , Histonas/metabolismo , Humanos , Neoplasias Hepáticas/metabolismo , Neoplasias Hepáticas/patologia , Camundongos , Camundongos Nus , Fosforilação/efeitos dos fármacos , Proteínas Serina-Treonina Quinases/metabolismo , Resultado do Tratamento
13.
Hepatogastroenterology ; 55(82-83): 609-14, 2008.
Artigo em Inglês | MEDLINE | ID: mdl-18613418

RESUMO

BACKGROUND/AIMS: We investigated a relationship between the risk factors for metabolic syndrome, such as obesity, diabetes mellitus, hypertension, and hyperlipidemia, and the pathogenesis and outcome of hepatocellular carcinoma (HCC). METHODOLOGY: One hundred twenty four patients who underwent curative resections for HCC were classified into 3 groups: those patients who were positive for hepatitis B surface antigen (group B), those positive for antibody to hepatitis C virus (group C), and those negative for both of them (non-B non-C) (group NBNC). The preoperative laboratory data, risk factors for metabolic syndrome, history of alcohol abuse, and outcome after surgery were investigated. The presence of non-alcoholic steatohepatitis (NASH) was also evaluated. RESULTS: The incidence of diabetes mellitus, hyperlipidemia, and alcohol abuse, and the serum level of triglyceride were significantly higher in group NBNC than in groups B or C. The risk factors for metabolic syndrome tended to lower the survival rates in group B and C, but not in group NBNC. Three of the 37 non-B non-C patients were associated with NASH. CONCLUSIONS: It is suggested that the pathogenesis of non-B non-C HCC may be more closely associated with the risk factors for metabolic syndrome than that of hepatitis virus related HCC.


Assuntos
Carcinoma Hepatocelular/etiologia , Fígado Gorduroso/complicações , Neoplasias Hepáticas/etiologia , Síndrome Metabólica/complicações , Adulto , Idoso , Idoso de 80 Anos ou mais , Carcinoma Hepatocelular/mortalidade , Progressão da Doença , Feminino , Humanos , Neoplasias Hepáticas/mortalidade , Masculino , Pessoa de Meia-Idade , Prognóstico , Fatores de Risco , Taxa de Sobrevida
14.
Hepatogastroenterology ; 55(82-83): 636-40, 2008.
Artigo em Inglês | MEDLINE | ID: mdl-18613423

RESUMO

BACKGROUND/AIMS: Although significantly higher serum levels of liver transaminases are commonly observed after hepatic resection, the factors responsible for the increase and the association between the increase and the postoperative course remain unclear. METHODOLOGY: The study population comprised 70 patients who had undergone hepatic resection except hepatectomy with vascular and biliary reconstruction. The relation between the perioperative factors and postoperative aspartic aminotransferase (AST) and alanine aminotransferase (ALT) elevations were analyzed. Outcome parameters, i.e., postoperative total bilirubin level, hospital stay and complications were also analyzed. RESULTS: The average maximum postoperative serum AST and ALT levels were 444.6 IU/L and 390.1 U/L. None of the preoperative factors examined, such as AST, ALT, associated liver disease, Liver Damage Classification, intraoperative hypotension, intraoperative blood loss or types of liver resection, were significantly correlated with liver enzyme elevations. The only factor that was significantly correlated was frequency of intermittent inflow occlusion (p < 0.001). The elevations of AST and ALT were not significantly correlated with length of hospital stay and postoperative serum bilirubin level. ALT also was not correlated to complications, whereas AST was significantly correlated to the frequency of the postoperative complications. CONCLUSIONS: The frequency of intermittent inflow occlusion is the only factor that affects the postoperative enzyme elevation.


Assuntos
Alanina Transaminase/sangue , Aspartato Aminotransferases/sangue , Hepatectomia/efeitos adversos , Hepatectomia/métodos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Perfusão
15.
J Am Coll Surg ; 204(1): 1-6, 2007 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-17189106

RESUMO

BACKGROUND: Partial hepatectomy and liver transplantation are considered curative treatments for small hepatocellular carcinoma (HCC) meeting the Milan criteria (solitary tumor <5 cm or up to 3 nodules <3 cm). This study was designed to clarify whether partial hepatectomy can be the first option in patients eligible for both treatments. STUDY DESIGN: All patients (n = 152) underwent curative surgical operation for primary HCC during 2000 to 2005 at our hospital. Eighty-seven patients met Milan criteria and the remaining 65 did not. Outcomes were examined according to Milan criteria. RESULTS: After partial hepatectomy, 3-year survival rate was 89.6% for the group that met Milan criteria, compared with 60.8% for the group that did not (p = 0.0044). Among patients with HCC who initially met the criteria, tumor recurrences were observed in 30 patients; 23 patients met criteria and 7 patients exceeded the criteria at first diagnosis of recurrence. Patients with recurrence within the criteria showed a higher 3-year survival rate compared with patients with recurrence exceeding the criteria (100% versus 19.8%; p < 0.0001). Analysis of clinicopathologic variables to predict mode of recurrence revealed tumor size (p < 0.0001) and lower histologic differentiation (p = 0.0326) as positive factors for recurrence exceeding Milan criteria. CONCLUSIONS: Our results suggest that it is an appropriate strategy to treat HCC patients who meet Milan criteria with partial hepatectomy. It should be noted that approximately one-tenth of patients who initially met Milan criteria experienced postoperative recurrence that exceeded the criteria.


Assuntos
Carcinoma Hepatocelular/cirurgia , Hepatectomia/métodos , Neoplasias Hepáticas/cirurgia , Recidiva Local de Neoplasia/epidemiologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Carcinoma Hepatocelular/diagnóstico por imagem , Carcinoma Hepatocelular/epidemiologia , Feminino , Seguimentos , Humanos , Incidência , Itália/epidemiologia , Neoplasias Hepáticas/diagnóstico por imagem , Neoplasias Hepáticas/epidemiologia , Masculino , Pessoa de Meia-Idade , Prognóstico , Estudos Retrospectivos , Taxa de Sobrevida , Tomografia Computadorizada por Raios X
16.
Hepatol Res ; 36(2): 86-93, 2006 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-17027597

RESUMO

BACKGROUND: Nitric oxide and endothelin-1 (ET-1) are believed to closely participate in the hepatic circulation. However, there are no clinical studies evaluating the participation of these two molecules in the hepatic circulation. PATIENTS AND METHODS: All 27 patients had liver tumors; 6 liver tumors were associated with liver cirrhosis and 12 patients had chronic hepatitis. Portal vein and hepatic arterial blood flow was measured with an electromagnetic flowmeter. Blood was sampled to quantitate endothelin-1 and nitrate/nitrite (NO(x)) from portal veins, peripheral veins and peripheral arteries. RESULTS: Serum ET-1 levels tended to be higher in patients with liver cirrhosis than patients with chronic hepatitis or patients with normal livers. There were no apparent differences in NO(x) concentrations among underlying liver disease states. Portal blood flow and estimated total hepatic blood flow was adversely correlated with ET-1 in portal veins with relatively higher correlation coefficients whereas arterial blood flow was not correlated to ET-1. On the other hand, arterial plasma ET-1 concentrations were not correlated to any type of blood flow. NO(x) concentrations were not correlated with any type of hepatic blood flow. The ratio of NO(x) to ET-1 in portal veins was correlated with portal blood flow and estimated hepatic blood flow. This correlation coefficients were higher than correlation coefficients between ET-1 concentrations in portal veins, and portal and hepatic blood flow. CONCLUSION: ET-1 levels in portal blood are significantly associated with portal blood flow and total hepatic blood flow in humans, and ratio of NO(x) to ET-1 is better indicators than either ET-1 or NO(x) alone. Although this study has limitations because it was carried out in a clinical setting, the data may contribute to the understanding of human hepatic hemodynamics.

17.
J Gastrointest Surg ; 9(2): 263-9, 2005 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-15694823

RESUMO

We report a rare case of a curative resection performed on a carcinoma developing in the remnant pancreas at 3 years 7 months after a pancreaticoduodenectomy for pancreatic cancer. A 63-year-old man underwent a pancreaticoduodenectomy for pancreatic cancer on November 1999. Because the celiac trunk was occluded by atherosclerosis, an aortohepatic bypass with a saphenous vein graft was performed simultaneously. In May 2003, tumor marker levels increased, and a tumor was detected in the remnant pancreas on computed tomography. There were no findings such as invasion into the surrounding tissue or distant metastasis, and therefore we removed the remnant pancreas in July 2003. Histopathologically, the tumor consisted of a well-differentiated tubular adenocarcinoma and was limited to the pancreas. Moreover, the anastomotic site of the pancreaticojejunostomy was negative for cancer, and some foci of papillary hyperplasia and goblet cell metaplasia of the pancreatic ductal epithelium, which was thought to be the precursor of the pancreatic cancer, were seen. These findings suggested that the tumor was a second primary cancer developing in the remnant pancreas. This case provided suggestive evidence for the development of pancreatic cancer, and the surgical procedure for a pancreaticoduodenectomy with occlusion of the celiac trunk is discussed.


Assuntos
Adenocarcinoma/cirurgia , Neoplasia Residual/cirurgia , Neoplasias Pancreáticas/cirurgia , Pancreaticoduodenectomia , Adenocarcinoma/patologia , Anastomose Cirúrgica , Dilatação Patológica , Humanos , Masculino , Pessoa de Meia-Idade , Neoplasia Residual/diagnóstico por imagem , Ductos Pancreáticos/patologia , Neoplasias Pancreáticas/diagnóstico por imagem , Neoplasias Pancreáticas/patologia , Tomografia Computadorizada por Raios X
18.
Am J Surg ; 189(4): 474-8, 2005 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-15820465

RESUMO

BACKGROUND: Laparoscopic/thoracoscopic intervention has been recently developed for hepatocellular carcinoma (HCC). However, no precise evaluation regarding this type of surgery has been performed. PATIENTS AND METHODS: A total of 33 laparoscopic and thoracoscopic treatments were performed on HCC patients, laparoscopic or thoracoscopic liver resection (LTR) in 15 patients and laparoscopic or thoracoscopic thermal ablation (LTA) in 18 patients. RESULTS: Postoperative hospital stay was 12.7 days after resection and 14.8 days after ablation. The 1- and 3- year actuarial survival rate were 100% and 80%, respectively, after LTR and 95% and 75%, respectively, after LTA. The 1- and 3- year disease-free survival rates were 75% and 40%, respectively, after LTR, and 60% and 28%, respectively, after LTA. CONCLUSION: LTR has the advantages of the curability of open surgery and less invasiveness of laparoscopic surgery. LTA is useful for tumors that cannot be percutaneously detected by ultrasound. Laparoscopic/thoracoscopic intervention is therefore considered an alternative means of treatment for selected HCC patients.


Assuntos
Carcinoma Hepatocelular/cirurgia , Ablação por Cateter/métodos , Laparoscopia/métodos , Neoplasias Hepáticas/cirurgia , Toracoscopia/métodos , Carcinoma Hepatocelular/mortalidade , Carcinoma Hepatocelular/patologia , Ablação por Cateter/efeitos adversos , Estudos de Coortes , Feminino , Seguimentos , Hepatectomia/efeitos adversos , Hepatectomia/métodos , Humanos , Japão , Laparoscopia/efeitos adversos , Neoplasias Hepáticas/mortalidade , Neoplasias Hepáticas/patologia , Masculino , Estadiamento de Neoplasias , Estudos Retrospectivos , Medição de Risco , Análise de Sobrevida , Toracoscopia/efeitos adversos , Resultado do Tratamento
19.
Hepatogastroenterology ; 50(53): 1217-9, 2003.
Artigo em Inglês | MEDLINE | ID: mdl-14571702

RESUMO

We report a case of hepatic artery embolization and partial portal vein arterialization for the treatment of a delayed massive hemorrhage after a pancreaticoduodenectomy. A 70-year-old male underwent a pancreaticoduodenectomy for the treatment of lower bile duct cancer. A slight discharge of pancreatic juice was recognized early during the postoperative period. A delayed massive hemorrhage occurred on postoperative day 34, resulting in hypotensive shock. Angiography and computed tomography examinations revealed bleeding from a pseudoaneurysm at the stump of the gastroduodenal artery and portal vein compression by the hematoma. Embolization of the stump of the gastroduodenal artery resulted in the total occlusion of the hepatic artery. We performed a partial portal vein arterialization via side-to-side anastomosis of a branch of the ileal artery and vein. The partial portal oxygen pressure increased from 70 mmHg to 90 mmHg. A liver abscess was recognized two weeks after the arterialization, but was successfully treated by percutaneous transhepatic drainage. The patient was discharged from hospital in good condition on postoperative day 69. Whether the partial portal vein arterialization was effective is unclear, but partial portal vein arterialization should be considered as an option in cases of total hepatic artery occlusion with impairment of portal blood flow.


Assuntos
Neoplasias dos Ductos Biliares/cirurgia , Embolização Terapêutica , Pancreaticoduodenectomia/efeitos adversos , Doenças Peritoneais/terapia , Hemorragia Pós-Operatória/terapia , Idoso , Falso Aneurisma/terapia , Artéria Hepática , Humanos , Masculino , Doenças Peritoneais/etiologia , Veia Porta , Hemorragia Pós-Operatória/etiologia
20.
No Shinkei Geka ; 30(10): 1111-5, 2002 Oct.
Artigo em Japonês | MEDLINE | ID: mdl-12404772

RESUMO

A case is reported of post-traumatic delayed appearance of a pseudoaneurysm on the posterior meningeal artery. In the immediate post-traumatic stage, the patient had mild disturbance of consciousness, mild subarachnoid hemorrhage, and mid-line skull fracture of the posterior cranial fossa. At 15 hours after the trauma, the patient suddenly developed deep coma and respiratory arrest. CT scanning showed further spreading of the subarachnoid hemorrhage and newly detected subdural hemorrhage. After the patient regained spontaneous respiration, cerebral angiography was performed 24 hours after admission. This initial angiography showed no aneurysm, but at 17 days after the trauma, follow-up angiography demonstrated the delayed appearance of an aneurysmal dilatation on the posterior meningeal artery. The aneurysm was resected surgically and proved to be a pseudoaneurysm. Having developed normal pressure hydrocephalus afterwards, the patient received a V-P shunt, and was discharged 150 days after the trauma with no major neurological deficit. We discussed the indication for and timing of angiography for detecting pseudoaneurysms. Posterior meningeal artery pseudoaneurysms should be resected surgically, because intravascular surgery through the vertebral artery involves considerable risk of embolic complications.


Assuntos
Falso Aneurisma/etiologia , Hemorragia Cerebral Traumática/etiologia , Traumatismos Cranianos Fechados/complicações , Artérias Meníngeas , Falso Aneurisma/cirurgia , Feminino , Humanos , Pessoa de Meia-Idade , Fraturas Cranianas/etiologia , Hemorragia Subaracnóidea/etiologia , Tomografia Computadorizada por Raios X
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA